cardiovascular-agents and Bronchitis

To determine the prevalence and analyze the most relevant clinical characteristics of three clinical phenotypes of COPD: emphysema (type 1), chronic bronchitis (type 2) or COPD-asthma (type 3).. Observational, multicenter study performed with 331 COPD patients recruited in pulmonology outpatient services. The stratification in three phenotypes was performed with imaging tests, pulmonary function, and a standardized clinical questionnaire.. The 43.2% presented an emphysematous phenotype, 44.7% were chronic bronchitic and the other 12.1% presented a phenotype showing mixed characteristics with asthma. There were no significant differences in the smoking level, in the gasometric values or time of disease evolution. Type 1 patients showed lower FEV1 values in comparison with types 2 and 3, 46.6% (21.1), 55.2% (21.2) and 54.4% (21.8), respectively (p < 0.05), and greater levels of dyspnea (p < 0.05). No significant differences were observed in the percentage of patients who had at least one exacerbation in the last year (68.8%, 63.9%, 64.9%; p = 0.25), in the number of exacerbations (p = 0.56), in the number of visits to the ER (total and due to COPD), or in the number of hospital admittances. Type 2 patients showed a greater prevalence of cardiovascular comorbidities and of sleep apnea syndrome (4.9%, 23.6% and 12.5%, respectively, p < 0.001).. In COPD, emphysematous patients present worse pulmonary function and greater dyspnea, although there were no differences in the use of hospital health care resources. The greater comorbidity in Group 2 patients may require specific strategies in this subgroup of patients.

Topics: Activities of Daily Living; Aged; Asthma; Bronchitis; Cardiovascular Agents; Chronic Disease; Comorbidity; Cross-Sectional Studies; Dyspnea; Female; Forced Expiratory Volume; Health Services; Humans; Male; Middle Aged; Phenotype; Prevalence; Pulmonary Disease, Chronic Obstructive; Pulmonary Emphysema; Quality of Life; Spain

Topics: Animals; Antineoplastic Agents, Phytogenic; Bronchitis; Cardiovascular Agents; Central Nervous System Depressants; Contraceptive Agents, Male; Humans; Male; Medicine, Chinese Traditional; Medicine, East Asian Traditional; Mice; Parasympatholytics; Plants, Medicinal; Rats

Topics: Anti-Bacterial Agents; Asthma; Bronchitis; Bronchodilator Agents; Cardiovascular Agents; Expectorants; Humans; Hydrocortisone; Hypnotics and Sedatives; Infusions, Parenteral; Muscle Relaxants, Central; Oxygen Inhalation Therapy; Parasympatholytics; Sputum; Sympathomimetics; Therapeutics; Toxicology; Triamcinolone

Topics: Anti-Infective Agents, Local; Bronchitis; Camphor; Cardiovascular Agents; Muscle Relaxants, Central; Vanillic Acid

Topics: Bronchitis; Cardiovascular Agents; Expectorants; Humans; Khellin; Muscle Relaxants, Central